HRVATSKA UDRUGA LEUKEMIJA I LIMFOMI (HULL) PRENOSI OBAVIJESTI – NAGLASKE S PREDAVANJA S 25-OG VIRTUALNOG EUROPSKOG HEMATOLOŠKOG KONGRESA (EHA) KOJE SE ODNOSE NA OBOLJELE OD KRONIČNE MIJELOIČNE LEUKEMIJE (KML)

For Chronic Myeloid Leukemia Patient Group Advocates

CML Advocates Network, EHA 2020
 
 

25th European Hematology Association Congress
Highlights from sessions dedicated to Chronic Myeloid Leukemia

From June 11-21 2020, the European Hematology Association (EHA) held its 25th Congress as an interactive virtual edition. 

Although it is the first time since 2010 that EHA Congress has not included a Patient Advocacy Track or any specific session on patient advocacy in the programme, many patients and patient organisations joined the virtual meeting thanks to a free access to the online platform provided by EHA.
 

Once again, the CML Advocates Network participated in this year’s congress with the attendance of several CML patient advocates such as Jan Geissler, Giora Sharf, Toni Montserrat, and Felice Bombaci as well as the active involvement of the network’s Executive Director Denis Costello and its Programme Manager Celia Marín.  Moreover, the network was proud to have been selected to present one abstract and one poster about our TFR for CML patients’ study.

Below you can find a short summary of the chronic myeloid leukemia highlights presented during this year's congress.

 

Satellite Symposium sponsored by Novartis
11th June 2020

“Expert insights into CML and classical MPNs treatment intervention: the ‘When’ and the ‘How’"

There were two interesting presentations on CML during this session:

  • Monitoring to achieve treatment goals in CML, H. Erba.

Dr. Erba concluded that the education of both physicians and patients regarding the benefit of monitoring could improve the quality of the CML molecular monitoring management.

 
  • Unmet needs in CML, with a focus on the 3L+, T. Hughes.
Dr. Hughes concluded that 20-30% of chronic phase CML patients will be refractory, resistant, or intolerant to two tyrosine kinase inhibitors (TKIs) and will need third-line therapy.
 

Best of Theme Session
19th June 2020
"Chronic myeloid neoplasms"

In this session, Drs. A. Almeida and C. Harrison conducted a review of what was presented at #EHA25Virtual on chronic myeloid leukemia, showcasing the most relevant and innovative topics such as resistant disease, novel inhibitors, novel approaches to treat CML including immunotherapy, management and adjustments of TKIs and combinations therapies to better treat CML patients.

 

Oral Abstract Session
19th June 2020
"CML Clinical"

This stimulating session looked at innovation in the field of CML with the following five Abstracts selected by the European Hematology Association:

 
Asciminib in heavily pretreated patients (pts) with Philadelphia chromosome-positive (PH+) chronic myeloid leukemia in chronic phase (CML-CP) sensitive to Tyrosine Kinase Inhibitor (TKI) therapy. Timothy Hughes (Australia)
 
Dr. Hughes concluded Asciminib monotherapy was well tolerated and showed promising clinical activity in patients with baseline BCR-ABL1≤ 1%.
To read the full Abstract, please, visit the EHA2020 Congress website HERE.
 
Major molecular response is the threshold for NGS analysis and resistant BCR-ABL1 mutation detection in CML. Katerina Machova Polakova (Czech Republic)
 
Dr. Polakova concluded in this study that the probability of mutation detection in patients who do not achieve better response than unstable MMR seems to be low and MMR is the level of measurable residual disease above which NGS of BCR-ABL1 can successfully be performed. 
To read the full Abstract, please, visit the EHA2020 Congress website HERE.